Embleema’s blockchain network offers a novel way to put patients at the center of clinical research by letting them own their health data, disrupting the slow, costly, manual and opaque process by which low-quality health data is currently collected by pharmaceutical companies through Contrat Research Organisation, to monitor the efficacy of new investigational drugs.
Embleema’s next building block is a Real-World Evidence (RWE) marketplace allowing patients to receive treatments and to connect with research. Sharing continuous, individual-patient level data will allow better monitoring of drugs in real-life and accelerate drug availability to patients.
Embleema ICO began on October 10, 2018. The ICO token supply represents 30% of the total token supply, so there is a total of 150,000,000 RWD tokens available, for 0.1734 each. The ICO funding target is 15,000,000 RWD, the funding cap is 150,000,000 RWD and is expected to end on March 31, 2019 or when the funding cap is reached.
Token Reserve Split (70%):
Embleema ICO features a bounty campaign.